Drug Target Review

APRIL 9, 2024

In 2005, he joined CNIO to lead the Genomic Instability Group where he has been ever since. These compounds were later licensed to the pharmaceutical industry for clinical development. Oscar Fernandez-Capetillo did his PhD in the University of The Basque Country working with mouse models of autoimmunity with Dr Ana Zubiaga.

RNA 64

RNA Cell Biology Clinical Development DNA 64

Common Sense for Drug Policy Blog

JUNE 6, 2024

Underground labs can be defined as illicit operations where IPEDs, most commonly anabolics androgenic steroids, are produced from these imported powders outside of registered pharmaceutical manufacture. 2014 ), and can broadly be characterised as social supply (Coomber et al. 2014 ; Begley et al.

Marketing 40

Marketing Drugs Production Pharmaceuticals 40

Drug Discovery World

JULY 25, 2023

These include two antibodies for modulating immune responses in cancer and autoimmunity, which are being advanced through pharmaceutical partnerships with Novartis and GlaxoSmithKline. So, in 2005, we were already in the clinic.

Immune Response 246

Immune Response Therapies Vaccine Production 246

The Pharma Data

SEPTEMBER 23, 2020

These new guidelines mean it will take extra time for pharmaceutical companies to prepare their applications and for the regulatory body to review the data. In 2005, it cleared an anthrax vaccine for military personnel who were at high risk of being exposed to an anthrax attack.

Vaccine 52

Vaccine FDA FDA Approval Pharmaceutical Companies 52

Agency IQ

NOVEMBER 10, 2023

Finally, a third regulation, Regulation (EC) No 2049/2005 , provides for reduced fees for small and medium-sized businesses (SMEs). Fees supplemental to the basic fees can be collected for authorization of additional strengths and pharmaceutical forms. literature monitoring), since national regulators charge their own fees.

Regulations 40

Regulations Pharmaceuticals Government Therapies 40

Sygnature Discovery

MARCH 24, 2022

The attraction of integration Originally from Kenya but a proud Yorkshirewoman – Leeds became her hometown at the age of 12 – Lynette gained her BSc in Pharmacology from the University of Sheffield in 2005. Back to Lynette, though.

Computational Chemistry 52

Computational Chemistry International Science Pharmaceuticals 52

The Pharma Data

FEBRUARY 22, 2022

Antoine Yver took over in 2021 as Chief Medical Officer of Centessa Pharmaceuticals, Inc. In 2005, he was appointed Senior Director of Oncology at Johnson & Johnson and in 2006, Executive Director of Oncology at Schering-Plough. Emile Voest obtained a PhD in medicine from the University of Utrecht.

DNA 52

DNA Clinical Trials Science Clinical Development 52

The Premier Consulting Blog

NOVEMBER 16, 2022

Excipients are ingredients separate from a drug’s active pharmaceutical ingredient (or drug substance) that are added to products to impart various properties such as binders, fillers, solubilizers, carriers, and pH adjusters. What does this qualification process look like, and what should sponsors know before introducing a novel excipient?

FDA 52

FDA Packaging Production Compliance 52

Vial

MAY 8, 2024

As technological advancements drive the pharmaceutical industry forward, the shift towards digitalization, particularly with electronic data capture (EDC) systems, has become increasingly prominent. This article offers a comparative analysis of Vial and Medrio, two leading companies at the forefront of EDC innovation.

Clinical Trials 52

Clinical Trials Trials Clinical Research Laboratories 52

The Pharma Data

DECEMBER 14, 2020

The Company’s proprietary tests and pharmaceutical company services aim to save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. Lung Cancer.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

MARCH 11, 2021

Actemra/RoActemra is part of a co-development agreement with Chugai Pharmaceutical Co., Ltd and has been approved in Japan since April 2005. Actemra/RoActemra is approved in more than 110 countries worldwide. Source link:[link].

Trials 52

Trials Hospitals Treatment Science 52

The Pharma Data

MARCH 20, 2023

Eisai submitted an application for manufacturing and marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023, in Japan. The Priority Review was granted by the Ministry of Health, Labour and Welfare (MHLW) on January 26, 2023.

Therapies 40

Therapies FDA Treatment Nurses 40

The Pharma Data

OCTOBER 20, 2020

To complement the clinical focus of the annual SABCS®, Baylor College of Medicine became a joint sponsor of SABCS® in 2005. The Symposium is attended by a large international audience of researchers, health professionals, physicians, oncologists, and those with a special interest in breast cancer from over 90 countries.

Research 52

Research International Treatment Regulations 52

The Pharma Data

MARCH 5, 2021

Actemra/RoActemra is part of a co-development agreement with Chugai Pharmaceutical Co., Ltd and has been approved in Japan since April 2005. Actemra/RoActemra is approved in more than 110 countries worldwide. Source link:[link].

FDA 52

FDA Disease FDA Approval Therapies 52

The Pharma Data

DECEMBER 15, 2020

TOMI-T1D is an international partnership between academia, the pharmaceutical industry and nonprofit organizations. Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. About Critical Path Institute.

Drug Development 40

Drug Development Clinical Trials Vaccine Trials 40

The Pharma Data

JUNE 2, 2022

(Nasdaq: GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day.

Science 52

Science Pharmaceuticals Engineering Production 52

The Pharma Data

JUNE 25, 2021

About the Collaboration between Eisai and BioArctic for Alzheimer’s Disease Since 2005, BioArctic has had a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of AD. is a leading global pharmaceutical company headquartered in Japan. About Eisai Co.,

Disease 40

Disease Treatment Therapies FDA 40

The Pharma Data

JULY 29, 2021

About the Collaboration between Eisai and BioArctic for Alzheimer’s Disease Since 2005, BioArctic has had a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of AD. is a leading global pharmaceutical company headquartered in Japan. About Eisai Co.,

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

New Drug Approvals

SEPTEMBER 8, 2024

2007.05.007 Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, LLC, 8 Clarke Drive, Cranbury, NJ 08512, USA Scheme 1. Seladelpar works to block bile acid synthesis. 1] Clinically, Seladelpar reduces pruritus and IL -31 in patients with primary biliary cholangitis. [6] 2007 Jul 15;17(14):3855-9. doi: 10.1016/j.bmcl.2007.05.007.

FDA 62

FDA Licensing Licensing FDA Approval 62

Drug Target Review

SEPTEMBER 20, 2023

Training AI/ML tools to predict results of otherwise complex and time-consuming calculations is gaining traction in pharmaceutical R&D. To really benefit from AI, the pharmaceutical industry must be more open to data sharing. Research and Development in the Pharmaceutical Industry | Congressional Budget Office [Internet].

Drugs 105

Drugs Metabolic Stability Computational Chemistry Pharmaceuticals 105

Drug Discovery World

SEPTEMBER 16, 2022

Since the approval of Kymirah in 2017, the cell and gene therapy sector has emerged as an exciting and innovative market, representing some of the most promising drugs the pharmaceutical industry has ever seen. . Last year, Pfizer opened a $68.5 million facility in Durham North Carolina to support the company’s gene therapy capabilities.

Therapies 130

Therapies Clinical Trials Production Trials 130

Drug Target Review

MAY 23, 2023

Algae – an overlooked resource for new therapies It is only in recent years that algae research has expanded beyond their potential for producing biodiesel, to also consider them as a bio-resource, not only for novel prebiotics but also for compounds with unique structures and pharmaceutically relevant bioactivities. 7 (Suppl 2), S4 (2005).

Drugs 75

Drugs Small Molecule Production Pharma Companies 75

New Drug Approvals

SEPTEMBER 7, 2024

Refer to WO 2004101742 A2, US 2005/0143320 Al, US 2006/0014821 Al, US 2009/0137818 Al, WO 2013049382 A2, WO 2013166319 A1, WO2018042343, WO2018023054, WO 2022013684, WO 2021252644, WO2022020711, WO 2022020242, US 11,174,231 B1, US 11,124,497 B1, WO 2005113580, and WO2006061714). Patent CN114524821A. WO2023177854 [link] Example 15.

RNA 62

RNA Virus Pharmaceuticals Therapies 62

The Pharma Data

NOVEMBER 25, 2020

Vifor Pharma Group is a global pharmaceuticals company. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. The company develops, manufactures and markets pharmaceutical products for precision patient care. Worldwide prevalence of anaemia 1993-2005. Am J Clin Nutr.

International 52

International Pharmaceuticals Pharmaceutical Companies Disease 52

The Pharma Data

NOVEMBER 2, 2020

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. Rein Piir, Head of Investor Relations at Oncopeptides, E-mail: rein.piir@oncopeptides.com. This information was submitted for publication at 8.00 CET on 3 November 2020. About Oncopeptides.

Marketing 40

Marketing Regulations Packaging Pharmaceutical Companies 40

Metabolite Tales Blog

MARCH 1, 2023

2018, 26, 965-972 [link] 4a Pharmaceutics, 2022, 14, 1001 [link] 5 Phys. 2017, 30, 1, 13–37 [link] 2a Drug Metab. 2006 , 34, 145-51 [link] 3 Drug Metab. 1980, 8, 34-38 [link] 4 J. Food Drug Anal. 2000, 2, 195-201 [link] 6 Biochem. 1966 98, 266-277 [link] 7 Metabolites. 2023, 13, 1, 92- [link] 8 J. 2018, 61, 5, 2041–205 [link] 9 ACS Chem.

Metabolic Stability 52

Metabolic Stability Pharmacokinetics Drugs Science 52

The Pharma Data

SEPTEMBER 2, 2021

“Our presence at ERS this year reiterates our commitment to patients through the further development of first-in-class therapies like Enerzair Breezhaler, as well as by exploring the potential of digital health companions and the carbon footprint of our solutions,” said Dominic Brittain, Respiratory Global Program Head, Novartis Pharmaceuticals. “As

Licensing 52

Licensing Licensing Treatment Therapies 52

Codon

APRIL 9, 2024

It was only in 2005, after the emergence of widespread resistance of P. Medical research groups were joined by pharmaceutical companies, chemical and spice factories, botany institutes, and insect science institutes. By 1971, more than 70 research institutions across a range of sectors joined the effort.

Drugs 129

Drugs Science Research Doctors 129

Agency IQ

JANUARY 26, 2024

Pharmacopeia (USP) and the FDA – to clarify whether the “actual ‘shelf life’ of many pharmaceutical products might be considerably longer than the expiration date that appears on the manufacturer’s container.” And per the FDA, “extension of drug product expiration dating periods is strictly voluntary for pharmaceutical manufacturers.”

Science 40

Science FDA Packaging Production 40

The Pharma Data

APRIL 27, 2021

About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI). ref: Alkhouli, M.

Treatment 40

Treatment Disease Pharmaceuticals Therapies 40

The Pharma Data

NOVEMBER 26, 2020

The company is working to obtain market approval in Europe for inhaled sedation in intensive care with the pharmaceutical IsoConDa® (isoflurane) during the second half of 2021. The company was founded in 2005 and is headquartered in Stockholm, Sweden , with medical device development in Ireland. [link].

Marketing 52

Marketing Drugs Treatment Regulations 52

The Pharma Data

AUGUST 31, 2021

part of the Janssen Pharmaceutical Companies of Johnson & Johnson; the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health; the Bill & Melinda Gates Foundation; and the HIV Vaccine Trials Network (HVTN). Since 2005, Janssen Vaccines & Prevention B.V.

Vaccine 52

Vaccine Trials Virus Treatment 52

SugarCone Biotech

MAY 28, 2019

A study, published in 2005, suggested that chloroquine could prevent SARS (the older virus) from infecting cells kept in culture. [2] In contrast, a weak hypothesis generates predictions that fail more often than not. One example is the hypothesis that hydroxychloroquine can be used to treat SARS-COV2 patients.

Vaccine 52

Vaccine Clinical Trials Virus Science 52

Agency IQ

FEBRUARY 2, 2024

In 2005, the guidance was updated to include non-cytotoxic drugs were gaining in importance. The pharmaceutical trade association EFPIA has released its comments on the concept paper , however. The document has been updated over time to implement advances in understanding cancer and drug development.

Clinical Trials 40

Clinical Trials Trials Treatment Production 40

Agency IQ

DECEMBER 15, 2023

March 2024 Standards of Performance for New Stationary Sources and Emission Guidelines for Existing Sources: Other Solid Waste Incineration Units Review Final Rule Stage 2060-AU60 EPA promulgated emissions standards for Other Solid Waste Incineration (OSWI) units on December 16, 2005. On September 14, 2018, the U.S.

Regulations 40

Regulations Compliance Production Government 40

Agency IQ

JUNE 16, 2023

The proposed revisions, the first since the FARR was promulgated in 2005 (70 FR 18074), clarify aspects of the initial rules and add provisions to address additional sources of particulate matter. Units covered under this rule include certain very small municipal waste combustion and institutional waste incineration units.

Regulations 40

Regulations Compliance Production Science 40

Policy Prescription

MARCH 19, 2021

He voted for the Pharmaceutical Market Access Act of 2003, H.R. An interesting paper from Duke University published in 2005 about why H.R. The question is: will the Biden administration and HHS Secretary Becerra defend it? And that gets us back to former Congressman Becerra’s vote in 2003. It’s noteworthy that it was a bipartisan vote.

Drugs 52

Drugs Pharmaceuticals Marketing 52